MCID: HLC007
MIFTS: 67

Helicobacter Pylori Infection

Categories: Cancer diseases, Gastrointestinal diseases, Genetic diseases

Aliases & Classifications for Helicobacter Pylori Infection

MalaCards integrated aliases for Helicobacter Pylori Infection:

Name: Helicobacter Pylori Infection 57 70
Helicobacter Pylori Infection, Susceptibility to 57 29 6 39
H. Pylori Infection, Susceptibility to 57 13
Helicobacter Pylori Infections 42
H. Pylori Infection 57

Characteristics:

OMIM®:

57 (Updated 05-Apr-2021)
Inheritance:
not determined


Classifications:



External Ids:

OMIM® 57 600263
MedGen 41 C1838332
UMLS 70 C0850666

Summaries for Helicobacter Pylori Infection

MedlinePlus : 42 Helicobacter pylori (H. pylori) is a type of bacteria that causes infection in the stomach. It is the main cause of peptic ulcers, and it can also cause gastritis and stomach cancer. About 30 to 40 percent of people in the United States get an H. pylori infection. Most people get it as a child. H. pylori usually does not cause symptoms. But it can break down the inner protective coating in some people's stomachs and cause inflammation. This can lead to gastritis or a peptic ulcer. Researchers aren't sure how H. pylori spreads. They think that it may spread by unclean food and water, or through contact with an infected person's saliva and other body fluids. A peptic ulcer causes a dull or burning pain in your stomach, especially when you have an empty stomach. It lasts for minutes to hours, and it may come and go for several days or weeks. It may also cause other symptoms, such as bloating, nausea, and weight loss. If you have the symptoms of a peptic ulcer, your health care provider will check to see whether you have H. pylori. There are blood, breath, and stool tests to check for H. pylori. In some cases, you may need an upper endoscopy, often with a biopsy. If you do have a peptic ulcer, the treatment is with a combination of antibiotics and acid-reducing medicines. You will need to be tested again after treatment to make sure the infection is gone. There is no vaccine for H. pylori. Since H. pylori might spread through unclean food and water, you might be able to prevent it if you Wash your hands after using the bathroom and before eating Eat properly prepared food Drink water from a clean, safe source NIH: National Institute of Diabetes and Digestive and Kidney Diseases

MalaCards based summary : Helicobacter Pylori Infection, also known as helicobacter pylori infection, susceptibility to, is related to peptic ulcer disease and atrophic gastritis, and has symptoms including nausea and vomiting, constipation and fever. An important gene associated with Helicobacter Pylori Infection is IFNGR1 (Interferon Gamma Receptor 1), and among its related pathways/superpathways are Signaling by GPCR and Innate Immune System. The drugs Roxithromycin and Azithromycin have been mentioned in the context of this disorder. Affiliated tissues include liver, heart and t cells, and related phenotypes are helicobacter pylori infection and Increased viability with MLN4924 (a NAE inhibitor)

OMIM® : 57 Helicobacter pylori is a microaerophilic, gram-negative bacterium that colonizes the gastric mucosa of approximately 50% of the world's population, and is a primary pathogenic factor in benign and malignant gastroduodenal disease (Warren and Marshall, 1983; Blaser and Parsonnet, 1994). Tomb et al. (1997) reported the complete sequence of the circular genome of H. pylori. The 1,667,867-bp genome contains 1,590 predicted coding sequences (genes). Sequence analysis of these genes indicated that the organism has systems for motility, for scavenging iron, and for DNA restriction and modification. Its survival in acid conditions depends, in part, on its ability to establish a positive inside-membrane potential in low pH. (600263) (Updated 05-Apr-2021)

Related Diseases for Helicobacter Pylori Infection

Diseases related to Helicobacter Pylori Infection via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 866)
# Related Disease Score Top Affiliating Genes
1 peptic ulcer disease 32.5 TNF IL1RN IL1B IL10 CYP2C19 CXCL8
2 atrophic gastritis 32.0 TNF IL1RN IL1B IL10 CXCL8
3 gastric ulcer 32.0 TNF IL1RN IL1B CYP2C19 CXCL8
4 peptic esophagitis 31.7 TNF IL1B CYP2C19 CXCL8
5 esophagitis 31.7 TNF IL1B IL10 CYP2C19 CXCL8
6 gastritis 31.6 TNF NOD1 IL1RN IL1B IL10 CYP2C19
7 gastroesophageal reflux 31.6 TNF IL1RN IL1B EGFR CYP2C19 CXCL8
8 duodenal ulcer 31.6 TNF NOD1 IL1RN IL1B IL10 CYP2C19
9 autoimmune gastritis 31.5 TNF IL1B IL10
10 fatty liver disease 31.4 TNF IL1B CXCL8 CASP3
11 hepatitis a 31.3 TNF IL1B IL10
12 diarrhea 31.3 TNF IL1B IL10 EGFR CXCL8
13 celiac disease 1 31.3 TNF IL1B IL10 CXCL8
14 pustulosis of palm and sole 31.2 TNF IL1RN CXCL8
15 bacterial infectious disease 31.2 TNF NOD1 IL1RN IL1B IL10 CXCL8
16 liver disease 31.2 TNF NFKB1 IL1B CXCL8 CASP3
17 chlamydia pneumonia 31.2 TNF IL1B IL10 CXCL8
18 thyroiditis 31.1 TNF IL1B IL10
19 disease by infectious agent 31.1 TNF IL1RN IL1B IL10 IFNGR1
20 irritable bowel syndrome 31.1 TNF IL1B IL10 CXCL8
21 chronic spontaneous urticaria 31.1 TNF CXCL8 CCL5
22 chlamydia 31.0 TNF NOD1 IL1B IL10 CXCL8
23 type 1 diabetes mellitus 31.0 TNF IL1RN IL1B IL10 CXCL8
24 stomatitis 31.0 TNF IL1B IL10 CXCL8
25 end stage renal disease 31.0 TNF IL1RN IL1B IL10
26 gastroenteritis 31.0 TNF IL1RN IL1B IL10 CXCL8
27 typhoid fever 30.9 TNF IL1B IFNGR1
28 exanthem 30.9 TNF IL1B IL10 EGFR CXCL8
29 alopecia areata 30.9 TNF IL1RN IL1B IL10
30 gastric cancer 30.8 PTPN11 PAK1 MET JUN IL1RN IL1B
31 lichen planus 30.8 TNF IL1B IL10 CXCL8
32 food allergy 30.8 TNF IL10 CXCL8
33 lipoprotein quantitative trait locus 30.8 TNF IL1RN IL1B IL10 CXCL8 CASP3
34 ulcerative colitis 30.8 TNF IL1RN IL1B IL10 CXCL8
35 proteasome-associated autoinflammatory syndrome 1 30.8 TNF IL1RN IL1B IL10 CXCL8 CCL5
36 periodontitis 30.8 TNF IL1RN IL1B IL10 CXCL8
37 brucellosis 30.7 TNF IL1RN IL10 CXCL8
38 allergic disease 30.7 TNF IL1B IL10 CXCL8 CCL5
39 crohn's colitis 30.7 TNF IL1B CXCL8
40 iridocyclitis 30.7 TNF IL1B IL10
41 pharyngitis 30.7 TNF IL1B CXCL8
42 aphthous stomatitis 30.7 TNF IL1RN IL1B IL10 CXCL8
43 otitis media 30.6 TNF IL1B IL10 CXCL8
44 uveitis 30.6 TNF IL1B IL10 CXCL8
45 bronchitis 30.6 TNF IL1B IL10 CXCL8 CCL5
46 dermatitis, atopic 30.6 TNF IL1B IL10 CXCL8 CCL5
47 mycobacterium fortuitum 30.6 IFNGR1 CXCL8
48 alcoholic liver cirrhosis 30.5 TNF IL1B IL10 CXCL8
49 acne 30.5 TNF IL1RN IL1B CXCL8
50 candidiasis 30.5 TNF IL1B IL10 CXCL8

Graphical network of the top 20 diseases related to Helicobacter Pylori Infection:



Diseases related to Helicobacter Pylori Infection

Symptoms & Phenotypes for Helicobacter Pylori Infection

Human phenotypes related to Helicobacter Pylori Infection:

31
# Description HPO Frequency HPO Source Accession
1 helicobacter pylori infection 31 HP:0005202

Symptoms via clinical synopsis from OMIM®:

57 (Updated 05-Apr-2021)
G I:
helicobacter pylori infection susceptibility

Clinical features from OMIM®:

600263 (Updated 05-Apr-2021)

UMLS symptoms related to Helicobacter Pylori Infection:


nausea and vomiting; constipation; fever; abdominal pain; pruritus; diarrhea; dyspepsia; icterus; heartburn; gastrointestinal gas

GenomeRNAi Phenotypes related to Helicobacter Pylori Infection according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased viability with MLN4924 (a NAE inhibitor) GR00250-A-2 9.85 CASP3 CHUK IL10 IL1B NFKB1 NFKBIA
2 Increased viability with MLN4924 (a NAE inhibitor) GR00250-A-3 9.85 JUN NFKB1
3 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.66 CASP3 CHUK CXCL8 IL10 IL1B JUN
4 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.66 CASP3 CHUK CXCL8 IL10 IL1B JUN
5 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-3 9.66 JUN NFKB1
6 Increased cell death in breast cancer cell lines (MCF10A, MDA-MB-435) GR00104-A-0 9.56 CASP3 CXCL8 PTPN11 TNF
7 Increased viability with paclitaxel GR00179-A-1 8.65 CASP3

MGI Mouse Phenotypes related to Helicobacter Pylori Infection:

46 (show all 21)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.44 ADAM10 CASP3 CHUK EGFR IFNGR1 IL10
2 hematopoietic system MP:0005397 10.44 ADAM10 CASP3 CCL5 CHUK EGFR IFNGR1
3 immune system MP:0005387 10.44 ADAM10 CASP3 CCL5 CHUK EGFR IFNGR1
4 cardiovascular system MP:0005385 10.41 ADAM10 CASP3 CHUK EGFR IFNGR1 IL10
5 homeostasis/metabolism MP:0005376 10.4 ADAM10 CASP3 CHUK EGFR IFNGR1 IL10
6 growth/size/body region MP:0005378 10.36 ADAM10 CASP3 CHUK EGFR IL10 IL1B
7 endocrine/exocrine gland MP:0005379 10.34 ADAM10 CASP3 CHUK EGFR IFNGR1 IL10
8 craniofacial MP:0005382 10.32 ADAM10 CASP3 CHUK EGFR IL10 IL1B
9 integument MP:0010771 10.31 ADAM10 CASP3 CHUK EGFR IFNGR1 IL10
10 mortality/aging MP:0010768 10.28 ADAM10 CASP3 CHUK EGFR IFNGR1 IL10
11 digestive/alimentary MP:0005381 10.27 ADAM10 CASP3 CHUK EGFR IFNGR1 IL10
12 embryo MP:0005380 10.22 ADAM10 CHUK EGFR IFNGR1 IL10 JUN
13 nervous system MP:0003631 10.13 ADAM10 CASP3 CHUK EGFR IFNGR1 IL10
14 liver/biliary system MP:0005370 10.11 CHUK EGFR IFNGR1 IL10 JUN MET
15 limbs/digits/tail MP:0005371 10.02 CHUK EGFR IL10 JUN MET PTPN11
16 muscle MP:0005369 10.01 CASP3 EGFR IL10 MET NFKB1 PAK1
17 neoplasm MP:0002006 9.97 CHUK EGFR IFNGR1 IL10 IL1B MET
18 normal MP:0002873 9.81 ADAM10 EGFR IL10 JUN MET NFKB1
19 no phenotypic analysis MP:0003012 9.8 CASP3 EGFR IL10 JUN MET PTPN11
20 respiratory system MP:0005388 9.65 CASP3 CHUK EGFR IL10 JUN MET
21 skeleton MP:0005390 9.44 ADAM10 CASP3 CHUK EGFR IFNGR1 IL10

Drugs & Therapeutics for Helicobacter Pylori Infection

Drugs for Helicobacter Pylori Infection (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 140)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Roxithromycin Approved, Investigational, Withdrawn Phase 4 80214-83-1 6915744 444037
2
Azithromycin Approved Phase 4 83905-01-5 447043 55185
3
Clarithromycin Approved Phase 4 81103-11-9 84029
4
carbamide peroxide Approved Phase 4 124-43-6
5
Nitazoxanide Approved, Investigational, Vet_approved Phase 4 55981-09-4 41684
6
Pantoprazole Approved Phase 4 102625-70-7 4679
7
Tinidazole Approved, Investigational Phase 4 19387-91-8 5479
8
Bismuth subsalicylate Approved, Vet_approved Phase 4 14882-18-9 53629521
9
Loperamide Approved Phase 4 53179-11-6 3955
10
Titanium dioxide Approved Phase 4 13463-67-7
11
Coal tar Approved Phase 4 8007-45-2
12
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
13
Phenylpropanolamine Approved, Vet_approved, Withdrawn Phase 4 14838-15-4 26934
14
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
15
Potassium citrate Approved, Investigational, Vet_approved Phase 4 866-84-2
16
Sodium citrate Approved, Investigational Phase 4 68-04-2
17
Minocycline Approved, Investigational Phase 4 10118-90-8 5281021
18
Trimebutine Approved Phase 4 39133-31-8
19
Ofloxacin Approved Phase 4 82419-36-1 4583
20
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
21
Rabeprazole Approved, Investigational Phase 4 117976-89-3 5029
22
Coenzyme Q10 Approved, Investigational, Nutraceutical Phase 4 303-98-0 5281915
23
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
24
Lactoferrin Investigational Phase 4 151186-19-5
25
Furazolidone Experimental, Vet_approved Phase 4 67-45-8 5323714 3435
26
Sulforaphane Investigational Phase 4 142825-10-3, 4478-93-7 5350
27
Meclocycline Investigational Phase 4 2013-58-3 5480760
28 Antidotes Phase 4
29 Antioxidants Phase 4
30 Antiviral Agents Phase 4
31 Bile Acids and Salts Phase 4
32 Ubiquinone Phase 4
33 Antibiotics, Antitubercular Phase 4
34 Antitubercular Agents Phase 4
35 Antidiarrheals Phase 4
36 Pharmaceutical Solutions Phase 4
37 Chlorpheniramine, phenylpropanolamine drug combination Phase 4
38 Antimalarials Phase 4
39 Citrate Phase 4
40 Respiratory System Agents Phase 4
41 Expectorants Phase 4
42 Anti-Infective Agents, Local Phase 4
43 Monoamine Oxidase Inhibitors Phase 4
44 Liver Extracts Phase 4
45 penicillins Phase 4
46 Fluoroquinolones Phase 4
47 Protective Agents Phase 4
48 Sulforafan Phase 4
49 Bifidobacterium Phase 4
50 Parasympatholytics Phase 4

Interventional clinical trials:

(show top 50) (show all 292)
# Name Status NCT ID Phase Drugs
1 Rabeprazole Based Sequential-Concommitant Hybrid Therapies for H. Pylori Infections Unknown status NCT01566643 Phase 4 RA5-RACM7;RA3-RACM7;RA7-RACM7
2 Analysis of the Impact of Helicobacter Pylori Infection and Eradication on Salivary Microbiome in Adults by 16S Pyrosequencing Unknown status NCT03730766 Phase 4 Esomeprazole;Amoxicillin;Bismuth Potassium Citrate
3 Comparison of the Efficacy of Clarithromycin-based Triple Therapy Versus Quadruple Therapies in the First Line Therapy of Helicobacter Pylori Infection- A Multicenter Randomized Comparative Trial Unknown status NCT01906879 Phase 4 triple, quadruple, non-bismuth quadruple therapy
4 10-Day Antimicrobial Susceptibility Testing Guided Triple Therapy Versus 14-Day Empirical Tailored Therapy for the First-line Treatment of Helicobacter Pylori Infection-A Randomized Controlled Trail Unknown status NCT03571230 Phase 4 two sensitive antibiotics(amoxicillin, clarithromycin, metronidazole, tinidazole, levofloxacin, furazolidone and tetracycline);two antibiotics based on personal medication history(amoxicillin,clarithromycin,furazolidone);one proton pump inhibitor(PPI);Colloidal Bismuth Pectin;two antibiotics for failed eradication(tetracyclin,furazolidone)
5 Comparison of the Efficacy of Triple Therapy With or Without Acetylcysteine in the First Line of Helicobacter Pylori Infection- A Multicenter Randomized Comparative Trial Unknown status NCT02249546 Phase 4 N-acetylcysteine + PPI-amoxicillin-clarithromycin;PPI-amoxicillin-clarithromycin
6 A Randomized, Double-blind, Placebo-controlled Study of the Usefulness of the Probiotic 'Lactobacillus Reuteri' in the Therapy of Quadruple Eradication of Helicobacter Pylori Infection in Usual Clinical Practice Unknown status NCT03150394 Phase 4
7 Helicobacter Pylori Eradication Rates of Concomitant Therapy and Tailored Therapy Based on 23S Ribosomal RNA Point Mutations Associated With Clarithromycin Resistance: A Multicenter Prospective Randomized Study Unknown status NCT03130452 Phase 4 Lansoprazole 30mg;Amoxicillin 1.0g Tab;Clarithromycin 500mg;Metronidazole 500 mg
8 Phase 4, Prospective, Randomized Study Comparing 14-day Non-bismuth Quadruple "Hybrid" and "Concomitant" Therapies for Helicobacter Pylori Eradication in Settings With High Clarithromycin Resistance Unknown status NCT01464060 Phase 4 PPI, amoxicillin, metronidazole and clarithromycin;PPI, amoxicillin, metronidazole and clarithromycin
9 Efficacy and Safety of a 14-day Modified Sequential Therapy for Refractory Helicobacter Pylori Infection: an Open Randomized Pilot Study Unknown status NCT03658733 Phase 4 esomeprazole, amoxicillin, tetracycline, furazolidone (only for the first 7 days), colloidal bismuth pectin (for the second 7 days);rabeprazole, amoxicillin, tetracycline, furazolidone (only for the first 7 days), colloidal bismuth pectin (for the second 7 days)
10 Efficacy and Safety of a 14-day Modified Sequential Therapy for Refractory Helicobacter Pylori Infection: a Pilot Study Unknown status NCT03616405 Phase 4 rabeprazole, amoxicillin, tetracycline, furazolidone (only for the first 7 days), colloidal bismuth pectin (for the second 7 days)
11 Comparison of Triple Therapy Regimens Effectiveness Over 10 Days and 14 Days in Eradication of Helicobacter Pylori Infection: Double Blind Randomized Clinical Trial Unknown status NCT03134378 Phase 4 Rabeprazole Sodium 20mg;Clarithromycin 500mg;Amoxicillin 500 Mg
12 Community-based Helicobacter Pylori Eradication With Two Sequential Antibiotic Regimens for the Residents and Migrants From a High-risk Area for Gastric Cancer Unknown status NCT00155389 Phase 4 Helicobacter pylori eradication
13 Efficacy of 10-day Concomitant Regimen Versus High Dose Dual Therapy in Anti-Helicobacter Pylori Rescue Therapy Unknown status NCT01265069 Phase 4 high dose dual therapy;concomitant therapy
14 Efficacy of Two Antimicrobial Susceptibility Testing Guided Antibiotic Selection Strategies in Salvage Helicobacter Pylori Treatment Unknown status NCT02988089 Phase 4 Clarithromycin susceptibility dependant strategy;2 susceptible antibiotics (amoxicillin, clarithromycin, metronidazole, tinidazole,levofloxacin, furazolidone and tetracycline );proton pump inhibitor (PPI) and Colloidal Bismuth Pectin;amoxicillin and clarithromycin or amoxicillin and furazolidone;amoxicillin and furazolidone or amoxicillin and tetracycline;amoxicillin and furazolidone or amoxicillin and Tinidazole or amoxicillin and Levofloxacin
15 The Efficacy of Probiotic Supplementation in the Reduction of Adverse Effects and Dysbiosis of Helicobacter Pylori Eradication Therapy - A Double Blind, Multi-center Randomized, Placebo Controlled Trial Unknown status NCT03722433 Phase 4 Vigiis 101-LAB and sequential therapy;Placebo and sequential therapy
16 Comparison of the Eradications Rates of Sequential Therapy Versus Concomitant Therapy of Treatment of Helicobacter Pylori Infection in Korea Unknown status NCT02108184 Phase 4 Sequential therapy 10 days;Sequential therapy 14 days;Concomitant therapy 10 days;Concomitant therapy 14 days
17 Tailored Therapy Versus Standard Triple Therapy for Helicobacter Pylori Eradication in Children: A Randomized Trial Unknown status NCT02635191 Phase 4 Tailored Group;Standard group
18 Doxycycline- and Furazolidone-containing Quadruple Regimen is Superior of Tailored Therapy as Rescue Treatment for Helicobacter Pylori Infection After Failure of Several Therapy Unknown status NCT02894268 Phase 4 Doxycycline;Furazolidone;Esomeprazole;Colloidal Bismuth Subcitrate;Sensitivity antibiotics
19 Food Effect on the Eradication Rate of H. Pylori With Triple Therapy With Esomeprazole Unknown status NCT02552641 Phase 4 Esomeprazole;Amoxicillin;Clarythromycin
20 A Prospective Open-label Study on Efficacy and Tolerability of Colloidal Bismuth Sub-citrate as Adjunctive Therapy to a Combination of Esomeprazole, Amoxicillin and Metronidazole for 10 Days for Helicobacter Pylori Elimination in Children Unknown status NCT03299725 Phase 4 colloidal bismuth sub-citrate
21 Comparison of the Efficacy of 14-day Sequential Therapy and 10-day Bismuth Quadruple Therapy in the Second Line Therapy for Helicobacter Pylori Infection: A Multi-center Randomized Trial Unknown status NCT03208426 Phase 4 Esomeprazole (S14);Esomeprazole (BQ10);Amoxicillin (ST14);Clarithromycin (ST14);Metronidazole (ST14);dibismuth trioxide 120mg (BQ10);Metronidazole (BQ10);tetracycline (BQ10)
22 Comparison of the Efficacy of Sequential Therapy and Bismuth Quadruple Therapy in the First Line and Second Line Therapy for Helicobacter Pylori Infection- A Multi-center Randomized Trial Unknown status NCT03156855 Phase 4 14-day sequential therapy;Bismuth quadruple therapy
23 Optimal Duration of Antimicrobial Susceptibility Test (AST) Guided Rescue Therapy for Helicobacter Pylori Infection Unknown status NCT02934048 Phase 4
24 Comparison of the Efficacy of Clarithromycin-based Triple Therapy for 14 Days Versus Sequential Therapy for 10 Days in the First Line Therapy for Helicobacter Pylori Infection- A Multicenter Randomized Comparative Trial Unknown status NCT01607918 Phase 4 D1-D5: (lansoprazole + amoxicillin ) D6-D10: (lansoprazole+clarithromycin +metronidazole);D1-D14: (lansoprazole + clarithromycin + amoxicillin)
25 Comparison of the Efficacy of Levofloxacin-based Sequential Therapy and Triple Therapy as Second Line Therapy for Refractory Helicobacter Pylori Infection- A Multi-center Randomized Trial Unknown status NCT01537055 Phase 4 levofloxacin-based sequential therapy;levofloxacin-based triple therapy for 10 days
26 Genotypic Resistance Guided Therapy in the Treatment of Helicobacter Pylori Infection Unknown status NCT01725906 Phase 4 empirical therapy;Genotypic resistance guided therapy
27 Helicobacter Pylori Eradication Using a Bismuth Quadruple Therapy Among Asymptomatically Infected Adults in El Paso, Texas: A Pilot Study. Unknown status NCT01335334 Phase 4 bismuth subcitrate potassium, metronidazole,tetracycline hydrochloride and omeprazole
28 Helicobacter Pylori Eradication Rates of Bismuth-containing Quadruple Therapy vs Modified Quadruple Therapy in Korea; Open-label, Randomized Controlled Trial Completed NCT03665428 Phase 4 PAMB treatment (modified quadruple therapy);PBMT treatment (bismuth-containing quadruple therapy)
29 The Efficacy of Sequential Therapy as Second Line Therapy for Refractory Helicobacter Pylori Infection - A Pilot Study Completed NCT00885417 Phase 4 Cravit-based sequential therapy
30 A Greek, Single Center, Randomized, Double Blind Controlled Clinical Study Comparing the 10-day Versus the 14-day Concomitant Proton Pump Inhibitor [PPI] + Amoxicillin + Metronidazole + Clarithromycin (PAMC) Therapeutic Scheme as First-line Treatment Strategy for the Eradication of H. Pylori Infection Completed NCT02959255 Phase 4 Esomeprazole
31 Comparison of 14-day Sequential and Hybrid Therapies for H Pylori Infection Completed NCT01085786 Phase 4 14-day sequential treatment;14-day hybrid treatment
32 Randomized Clinical Trial: the Comparison of 15-day Sequential and 10-day Sequential Therapy to PPI-based Triple Therapy for Helicobacter Pylori Infection in Korea Completed NCT01887249 Phase 4 Clarithromycin;metronidazole;esomeprazole
33 Visiting Staff, Division of Gastroenterology and Department of Internal Medicine, Mackay Memorial Hospital, Taipei, Taiwan Completed NCT03524833 Phase 4 Metronidazole;Lansoprazole, Amoxicillin, Metronidazole
34 Visiting Staff, Division of Gastroenterology and Department of Internal Medicine, Mackay Memorial Hospital, Taipei, Taiwan Completed NCT03516669 Phase 4 Clarithromycin;Amoxicillin, Clarithromycin
35 The Efficacy of Susceptibility Test -Driven Sequential Therapy as the Third Line Therapy for Refractory Helicobacter Pylori Infection Completed NCT01032655 Phase 4 susceptibility test guided sequential therapy
36 THE EFFECT OF HELICOBACTER PYLORI ERADICATION THERAPY TO GASTRIC WALL THICKNESS BEFORE THE LAPAROSCOPIC SLEEVE GASTRECTOMY Completed NCT03757650 Phase 4 Bismuth Subsalicylate
37 Efficacy of High-dose Dual Therapy Versus Bismuth-containing Quadruple Therapy for First-line Treatment of Helicobacter Pylori Infection - A Prospective, Randomized, Comparative Study Completed NCT02483715 Phase 4 High-dose dual therapy (rabeprazole, amoxicillin);Bismuth-containing quadruple therapy (rabeprazole, tripotassium dicitrate bismuthate, metronidazole, tetracycline)
38 Efficacies of Antimicrobial Susceptibility-Guided Versus Empirical Therapy for Rescue Treatment of Helicobacter Pylori Infection-A Randomized Clinical Trial Completed NCT03658746 Phase 4 two sensitive antibiotics(amoxicillin, clarithromycin, metronidazole, tinidazole, levofloxacin, furazolidone and tetracycline);one proton pump inhibitor, colloidal bismuth pectin;two antibiotics based on personal medication history(amoxicillin,levofloxacin, furazolidone)
39 Visiting Staff, Division of Gastroenterology and Department of Internal Medicine, Mackay Memorial Hospital, Taipei, Taiwan Completed NCT03521726 Phase 4 Amoxicillin;Rabeprazole, Amoxicillin
40 Intraluminal Therapy for Helicobacter Pylori Infection Completed NCT03124420 Phase 4 Lansoprazole;Amoxicillin;Clarithromycin
41 A Randomized Clinical Trial of Clarithromycin/Bismuth Containing Quadruple Therapy for Helicobacter Pylori First-line Treatment Completed NCT02732249 Phase 4 Esomeprazole;Bismuth Potassium Citrate;Clarithromycin;Metronidazole
42 Visiting Staff, Division of Gastroenterology and Department of Internal Medicine, Mackay Memorial Hospital, Taipei, Taiwan Completed NCT03832465 Phase 4 Levofloxacin film-coated tablet;Levofloxacin intravenous solution
43 Comparison of Dexlansoprazole-based Triple and Rabeprazole-based Triple Therapies for Helicobacter Pylori Infection Completed NCT02541786 Phase 4 dexlansoprazole based triple therapy;rabeprazole-based triple therapy
44 Efficacy of High-dose Dual Therapy Versus Bismuth-containing Quadruple Therapy for Rescue Treatment of Helicobacter Pylori Infection - A Prospective, Randomized, Comparative Study Completed NCT02490839 Phase 4 High-dose dual therapy (rabeprazole, amoxicillin);Bismuth-containing quadruple therapy (rabeprazole, tripotassium dicitrate bismuthate, metronidazole, tetracycline)
45 Comparison of 7-day Triple, 10-day Sequential, and 7-day Concomitant Therapies for Helicobacter Pylori Infection in Taiwan Completed NCT01769365 Phase 4 7-day quadruple therapy;10-day sequential therapy;7-day standard triple therapy
46 Efficacy of High Dose of Amoxicillin And Metronidazole Plus Bismuth For Helicobacter Pylori Treatment In Naive Patients : A Randomized Clinical Trial Completed NCT03557437 Phase 4 Esomeprazole;Amoxicillin, Metronidazole;Bismuth Potassium Citrate
47 Study the Efficacy of Lactoferrin in Helicobacter Pylori Eradication Either With Standard Triple Therapy or Sequential Therapy in Egyptian Patients Completed NCT04445948 Phase 4 Esomeprazole 40 milligrams Oral Tablet;Amoxicillin 1000 milligrams tablets;Clarithromycin 500 milligrams Tablets;MetroNIDAZOLE 500 milligrams Oral Tablet;Lactoferrin Bovine sachets 200 milligrams
48 Adding Bismuth to Rabeprazole-based First-line Triple Therapy Does Not Improve the Eradication of Helicobacter Pylori Completed NCT03108287 Phase 4 RAK therapy;RBAK therapy
49 Antibiotic Susceptibility-based Tailored Therapy for Helicobacter Pylori Treatment in Patients With Penicillin Allergy: a Prospective Clinical Trial Completed NCT03708848 Phase 4 Esomeprazole;Bismuth Potassium Citrate;Clarithromycin;Metronidazole;Levofloxacin;Tetracycline
50 Efficacy of Antibiotic Susceptibility-based Tailored Versus Empiric Therapy for Helicobacter Pylori First-line Treatment:a Randomized Clinical Trial Completed NCT02935010 Phase 4 Esomeprazole;Bismuth Potassium Citrate;Amoxicillin;Clarithromycin;Metronidazole;Levofloxacin

Search NIH Clinical Center for Helicobacter Pylori Infection

Genetic Tests for Helicobacter Pylori Infection

Genetic tests related to Helicobacter Pylori Infection:

# Genetic test Affiliating Genes
1 Helicobacter Pylori Infection, Susceptibility to 29 IFNGR1

Anatomical Context for Helicobacter Pylori Infection

MalaCards organs/tissues related to Helicobacter Pylori Infection:

40
Liver, Heart, T Cells, Whole Blood, Neutrophil, Kidney, Endothelial

Publications for Helicobacter Pylori Infection

Articles related to Helicobacter Pylori Infection:

(show top 50) (show all 12868)
# Title Authors PMID Year
1
Genomewide linkage analysis identifies polymorphism in the human interferon-gamma receptor affecting Helicobacter pylori infection. 6 57 61
12516030 2003
2
Natural antibiotic function of a human gastric mucin against Helicobacter pylori infection. 57 61
15310903 2004
3
Transmission of Helicobacter pylori infection. 57 61
7672655 1995
4
Expression of a human alpha-1,3/4-fucosyltransferase in the pit cell lineage of FVB/N mouse stomach results in production of Leb-containing glycoconjugates: a potential transgenic mouse model for studying Helicobacter pylori infection. 61 57
7878011 1995
5
Helicobacter pylori infection: genetic and environmental influences. A study of twins. 61 57
8185146 1994
6
Seroprevalence of helicobacter pylori infection in couples. 61 57
2037687 1991
7
GWAS of peptic ulcer disease implicates Helicobacter pylori infection, other gastrointestinal disorders and depression. 42 61
33608531 2021
8
A genome-wide association study identifies two susceptibility loci for duodenal ulcer in the Japanese population. 57
22387998 2012
9
A regulatory polymorphism in interferon-gamma receptor 1 promoter is associated with the susceptibility to chronic hepatitis B virus infection. 6
19488747 2009
10
Genetic variation in PSCA is associated with susceptibility to diffuse-type gastric cancer. 57
18488030 2008
11
Helicobacter exploits integrin for type IV secretion and kinase activation. 57
17943123 2007
12
Polymorphism within the interferon-gamma/receptor complex is associated with pulmonary tuberculosis. 6
16690980 2006
13
Distinguishing human ethnic groups by means of sequences from Helicobacter pylori: lessons from Ladakh. 57
15051885 2004
14
Protective immunity against Helicobacter is characterized by a unique transcriptional signature. 57
14528007 2003
15
Treatment of Helicobacter gastritis with IL-4 requires somatostatin. 57
14555768 2003
16
Mice deficient in protein tyrosine phosphatase receptor type Z are resistant to gastric ulcer induction by VacA of Helicobacter pylori. 57
12598897 2003
17
Lewis enzyme (alpha1-3/4 fucosyltransferase) polymorphisms do not explain the Lewis phenotype in the gastric mucosa of a Portuguese population. 57
12730721 2003
18
Helicobacter pylori and gastrointestinal tract adenocarcinomas. 57
11902583 2002
19
Polymorphisms of two fucosyltransferase genes (Lewis and Secretor genes) involving type I Lewis antigens are associated with the presence of anti-Helicobacter pylori IgG antibody. 57
11535550 2001
20
The complete genome sequence of the gastric pathogen Helicobacter pylori. 57
9252185 1997
21
Parasitism by the "slow" bacterium Helicobacter pylori leads to altered gastric homeostasis and neoplasia. 57
8040281 1994
22
Gene structure of the Helicobacter pylori cytotoxin and evidence of its key role in gastric disease. 57
8163943 1994
23
Attachment of Helicobacter pylori to human gastric epithelium mediated by blood group antigens. 57
8018146 1993
24
Purification and characterization of the vacuolating toxin from Helicobacter pylori. 57
1587837 1992
25
Unidentified curved bacilli on gastric epithelium in active chronic gastritis. 57
6134060 1983
26
Parameters of immunoglobulin extraction from dried blood spot cards and immunoassays for detection of antibody response to pathogens including the novel SARS-CoV-2. 42
33582147 2021
27
Role of endoscopy in suspicion of atrophic gastritis with and without intestinal metaplasia in comparison to histopathology. 42
33639688 2021
28
Review article: potassium-competitive acid blockers for the treatment of acid-related disorders. 61
33592125 2021
29
Gastrointestinal adverse reactions reduce the success rate of Helicobacter pylori eradication therapy: A multicenter prospective cohort study. 61
33368891 2021
30
Regular arrangement of collecting venules under endoscopy for predicting a Helicobacter pylori-negative stomach: A systematic review and meta-analysis. 61
33097281 2021
31
"Helicobacter pylori in familial mediterranean fever: A series of 120 patients from literature and from france". 61
33586832 2021
32
The Use of Fecal Calprotectin Testing in Paediatric Disorders: A Position Paper of the European Society for Paediatric Gastroenterology and Nutrition Gastroenterology Committee. 61
33716293 2021
33
Helicobacter pylori infection is associated with the co-occurrence of bacteria in the oral cavity and the gastric mucosa. 61
33596339 2021
34
Adherence to Maastricht V/Florence consensus report for the management of Helicobacter pylori infection among primary care physicians and medical students in Croatia: A cross-sectional study. 61
33368852 2021
35
Eradication of Helicobacter pylori infection decreases risk for dyslipidemia: A cohort study. 61
33508177 2021
36
Update on the association between non-alcoholic fatty liver disease and Helicobacter pylori infection. 61
32991019 2021
37
ABH and Lewis blood group systems and their relation to diagnosis and risk of Helicobacter pylori infection. 61
33253856 2021
38
Prevalence and associated risk factors of Helicobacter pylori infection in the Wuwei cohort of north-western China. 61
33159827 2021
39
Bismuth salts with versus without acid suppression for Helicobacter pylori infection: A transmission electron microscope study. 61
33740276 2021
40
Gastric Acid Powered Nanomotors Release Antibiotics for In Vivo Treatment of Helicobacter pylori Infection. 61
33619851 2021
41
A standardized protocol improves testing rates for Helicobacter Pylori among inpatients with peptic ulcer disease. 61
33720493 2021
42
Gastroprotection in patients on antiplatelet and/or anticoagulant therapy: a position paper of National Association of Hospital Cardiologists (ANMCO) and the Italian Association of Hospital Gastroenterologists and Endoscopists (AIGO). 61
33279389 2021
43
Diet and cancer of the esophagus and stomach. 61
33315794 2021
44
Recent Advances in the Definition and Management of Functional Dyspepsia. 61
32612016 2021
45
Direct detection of Helicobacter pylori from biopsies of patients in Lagos, Nigeria using real-time PCR-a pilot study. 61
33750448 2021
46
PROBIOTICS IN GASTROINTESTINAL DISEASES: ALL THAT GLITTERS IS NOT GOLD. 61
33752212 2021
47
In vivo activation of pH-responsive oxidase-like graphitic nanozymes for selective killing of Helicobacter pylori. 61
33790299 2021
48
Alterations in mucosa-associated microbiota in the stomach of patients with gastric cancer. 61
33770413 2021
49
Cost-Effectiveness of Empirical Bismuth-Based Quadruple Therapy and Tailored Therapy After Clarithromycin Resistance Tests for Helicobacter pylori Eradication. 61
33755825 2021
50
Molecular Mechanism of Helicobacter pylori-Induced Gastric Cancer. 61
32926335 2021

Variations for Helicobacter Pylori Infection

ClinVar genetic disease variations for Helicobacter Pylori Infection:

6
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 IFNGR1 IFNGR1, -56C-T SNV risk factor 17953 GRCh37:
GRCh38:
2 IFNGR1 NM_000416.3(IFNGR1):c.974C>T (p.Pro325Leu) SNV Uncertain significance 992563 GRCh37: 6:137519664-137519664
GRCh38: 6:137198527-137198527

Expression for Helicobacter Pylori Infection

LifeMap Discovery
Genes differentially expressed in tissues of Helicobacter Pylori Infection patients vs. healthy controls: 35 (show top 50) (show all 94)
# Gene Description Tissue Up/Dn Fold Change (log2) P value
1 FDCSP follicular dendritic cell secreted protein Gastrointestinal Tract,Stomach + 9.19 0.000
2 DMBT1 deleted in malignant brain tumors 1 Gastrointestinal Tract,Stomach + 7.69 0.000
3 REG3G regenerating family member 3 gamma Gastrointestinal Tract,Stomach + 6.56 0.000
4 CR2 complement C3d receptor 2 Gastrointestinal Tract,Stomach + 6.52 0.000
5 OLFM4 olfactomedin 4 Gastrointestinal Tract,Stomach + 6.34 0.001
6 CXCL13 C-X-C motif chemokine ligand 13 Gastrointestinal Tract,Stomach + 6.24 0.000
7 REG3A regenerating family member 3 alpha Gastrointestinal Tract,Stomach + 6.15 0.000
8 CD19 CD19 molecule Gastrointestinal Tract,Stomach + 5.25 0.000
9 FCRL3 Fc receptor like 3 Gastrointestinal Tract,Stomach + 5.18 0.000
10 CXCR5 C-X-C motif chemokine receptor 5 Gastrointestinal Tract,Stomach + 5.12 0.000
11 SAA2 serum amyloid A2 Gastrointestinal Tract,Stomach + 4.81 0.000
12 MS4A1 membrane spanning 4-domains A1 Gastrointestinal Tract,Stomach + 4.76 0.000
13 CCL20 C-C motif chemokine ligand 20 Gastrointestinal Tract,Stomach + 4.64 0.000
14 ABCA12 ATP binding cassette subfamily A member 12 Gastrointestinal Tract,Stomach + 4.60 0.000
15 SAA1 serum amyloid A1 Gastrointestinal Tract,Stomach + 4.59 0.000
16 NLRP7 NLR family pyrin domain containing 7 Gastrointestinal Tract,Stomach + 4.56 0.000
17 CCL19 C-C motif chemokine ligand 19 Gastrointestinal Tract,Stomach + 4.52 0.000
18 VNN1 vanin 1 Gastrointestinal Tract,Stomach + 4.51 0.000
19 BPIFB1 BPI fold containing family B member 1 Gastrointestinal Tract,Stomach + 4.48 0.000
20 AFAP1-AS1 AFAP1 antisense RNA 1 Gastrointestinal Tract,Stomach + 4.47 0.000
21 CCR7 C-C motif chemokine receptor 7 Gastrointestinal Tract,Stomach + 4.38 0.000
22 CXCL1 C-X-C motif chemokine ligand 1 Gastrointestinal Tract,Stomach + 4.33 0.000
23 CHI3L1 chitinase 3 like 1 Gastrointestinal Tract,Stomach + 4.30 0.000
24 DEFB4A defensin beta 4A Gastrointestinal Tract,Stomach + 4.25 0.000
25 LAIR2 leukocyte associated immunoglobulin like receptor 2 Gastrointestinal Tract,Stomach + 4.22 0.000
26 TCL1A TCL1 family AKT coactivator A Gastrointestinal Tract,Stomach + 4.16 0.000
27 SELL selectin L Gastrointestinal Tract,Stomach + 4.14 0.000
28 S100A8 S100 calcium binding protein A8 Gastrointestinal Tract,Stomach + 4.09 0.000
29 FCRL5 Fc receptor like 5 Gastrointestinal Tract,Stomach + 3.95 0.000
30 TLR10 toll like receptor 10 Gastrointestinal Tract,Stomach + 3.95 0.000
31 C3 complement C3 Gastrointestinal Tract,Stomach + 3.95 0.000
32 LCN2 lipocalin 2 Gastrointestinal Tract,Stomach + 3.92 0.000
33 MMP7 matrix metallopeptidase 7 Gastrointestinal Tract,Stomach + 3.88 0.000
34 CD28 CD28 molecule Gastrointestinal Tract,Stomach + 3.80 0.000
35 BLK BLK proto-oncogene, Src family tyrosine kinase Gastrointestinal Tract,Stomach + 3.80 0.000
36 CD22 CD22 molecule Gastrointestinal Tract,Stomach + 3.80 0.000
37 FCRL2 Fc receptor like 2 Gastrointestinal Tract,Stomach + 3.78 0.000
38 CXCL8 C-X-C motif chemokine ligand 8 Gastrointestinal Tract,Stomach + 3.77 0.000
39 FCRL4 Fc receptor like 4 Gastrointestinal Tract,Stomach + 3.72 0.000
40 CXCL2 C-X-C motif chemokine ligand 2 Gastrointestinal Tract,Stomach + 3.69 0.000
41 CD180 CD180 molecule Gastrointestinal Tract,Stomach + 3.68 0.000
42 PLA2G7 phospholipase A2 group VII Gastrointestinal Tract,Stomach + 3.66 0.000
43 FCAMR Fc fragment of IgA and IgM receptor Gastrointestinal Tract,Stomach + 3.65 0.000
44 AQP9 aquaporin 9 Gastrointestinal Tract,Stomach + 3.64 0.000
45 FCRLA Fc receptor like A Gastrointestinal Tract,Stomach + 3.63 0.000
46 AIM2 absent in melanoma 2 Gastrointestinal Tract,Stomach + 3.63 0.000
47 LTF lactotransferrin Gastrointestinal Tract,Stomach + 3.63 0.000
48 KRT6B keratin 6B Gastrointestinal Tract,Stomach + 3.60 0.000
49 C6 complement C6 Gastrointestinal Tract,Stomach - 3.60 0.000
50 NEURL3 neuralized E3 ubiquitin protein ligase 3 Gastrointestinal Tract,Stomach + 3.59 0.000
Search GEO for disease gene expression data for Helicobacter Pylori Infection.

Pathways for Helicobacter Pylori Infection

Pathways related to Helicobacter Pylori Infection according to GeneCards Suite gene sharing:

(show top 50) (show all 170)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.33 TNF PTPN11 PAK1 NFKBIA NFKB1 MET
2
Show member pathways
14.07 TNF PTPN11 PAK1 NOD1 NFKBIA NFKB1
3
Show member pathways
14.01 TNF PAK1 NFKBIA NFKB1 MET JUN
4
Show member pathways
13.99 TNF PAK1 NFKBIA NFKB1 MET JUN
5
Show member pathways
13.85 TNF NFKBIA NFKB1 MET JUN IL1RN
6
Show member pathways
13.74 TNF PTPN11 PAK1 NFKBIA NFKB1 MET
7
Show member pathways
13.63 TNF PTPN11 PAK1 NFKB1 MET JUN
8
Show member pathways
13.62 TNF PAK1 NFKB1 MET IL1B IL10
9
Show member pathways
13.55 PAK1 NFKB1 JUN EGFR CXCL8 CXCL1
10
Show member pathways
13.41 TNF PAK1 NFKBIA NFKB1 JUN IL1B
11
Show member pathways
13.37 TNF NFKBIA NFKB1 JUN IL1B IL10
12
Show member pathways
13.35 TNF PTPN11 NOD1 NFKB1 MET IL1RN
13
Show member pathways
13.28 TNF PAK1 NFKBIA NFKB1 JUN EGFR
14
Show member pathways
13.2 TNF PTPN11 PAK1 NFKBIA NFKB1 MET
15
Show member pathways
13.18 PAK1 NFKB1 MET JUN EGFR CHUK
16
Show member pathways
13.17 PAK1 NFKBIA NFKB1 MET JUN CHUK
17
Show member pathways
13.13 TNF NFKB1 MET EGFR CHUK CASP3
18
Show member pathways
13.1 PAK1 NFKBIA NFKB1 JUN CXCL8 CXCL1
19 13.08 NFKBIA NFKB1 MET JUN IFNGR1 EGFR
20
Show member pathways
13.07 TNF NFKBIA NFKB1 JUN IL1B IFNGR1
21
Show member pathways
13.06 PTPN11 NFKBIA NFKB1 JUN EGFR CHUK
22 13.04 TNF PTPN11 NFKBIA NFKB1 IL1B IFNGR1
23 13 TNF PAK1 NFKB1 MET JUN IL1B
24
Show member pathways
12.95 TNF PTPN11 NFKBIA NFKB1 JUN CHUK
25
Show member pathways
12.95 TNF NOD1 NFKBIA NFKB1 JUN IL1RN
26
Show member pathways
12.93 PTPN11 PAK1 NFKBIA NFKB1 MET JUN
27
Show member pathways
12.92 TNF NFKBIA NFKB1 MET IL1B EGFR
28
Show member pathways
12.92 TNF NFKBIA NFKB1 JUN IL1B IFNGR1
29
Show member pathways
12.91 PTPN11 PAK1 NFKB1 MET EGFR CHUK
30
Show member pathways
12.91 TNF PTPN11 PAK1 NOD1 NFKBIA NFKB1
31
Show member pathways
12.9 PTPN11 NFKBIA NFKB1 MET EGFR CHUK
32
Show member pathways
12.88 TNF NFKBIA NFKB1 JUN CHUK CASP3
33
Show member pathways
12.87 TNF PAK1 NFKBIA NFKB1 JUN IL10
34
Show member pathways
12.86 TNF PAK1 NFKB1 JUN EGFR CASP3
35
Show member pathways
12.85 TNF NFKBIA NFKB1 JUN IL1B IL10
36
Show member pathways
12.84 TNF PAK1 NFKBIA NFKB1 JUN IL1B
37
Show member pathways
12.81 PTPN11 PAK1 NFKB1 MET JUN EGFR
38 12.81 TNF NOD1 NFKBIA NFKB1 IL1RN IL1B
39
Show member pathways
12.81 TNF PTPN11 PAK1 NFKBIA NFKB1 IL1B
40
Show member pathways
12.78 TNF PTPN11 NFKBIA NFKB1 JUN CHUK
41
Show member pathways
12.75 NOD1 NFKBIA NFKB1 IL1B CHUK CCL5
42
Show member pathways
12.74 PTPN11 PAK1 NFKBIA NFKB1 JUN IL1RN
43
Show member pathways
12.72 TNF PTPN11 PAK1 JUN IFNGR1 CASP3
44
Show member pathways
12.71 NFKBIA NFKB1 MET JUN IL1B EGFR
45
Show member pathways
12.7 TNF NFKBIA NFKB1 CXCL8 CHUK
46
Show member pathways
12.69 TNF PTPN11 PAK1 NFKBIA NFKB1 JUN
47
Show member pathways
12.66 PAK1 NFKB1 JUN EGFR CASP3
48
Show member pathways
12.64 PAK1 NFKBIA NFKB1 JUN IL10 CHUK
49
Show member pathways
12.62 PTPN11 PAK1 NFKBIA NFKB1 JUN CHUK
50
Show member pathways
12.61 PAK1 NFKBIA NFKB1 IL1B CHUK

GO Terms for Helicobacter Pylori Infection

Cellular components related to Helicobacter Pylori Infection according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.65 TNF NFKB1 MET IL1RN IL1B IL10
2 I-kappaB/NF-kappaB complex GO:0033256 8.62 NFKBIA NFKB1

Biological processes related to Helicobacter Pylori Infection according to GeneCards Suite gene sharing:

(show top 50) (show all 60)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 10.23 TNF NFKBIA NFKB1 MET JUN IL10
2 signal transduction GO:0007165 10.21 PAK1 NOD1 NFKB1 MET IL1RN IL1B
3 apoptotic process GO:0006915 10.17 PAK1 NOD1 NFKBIA NFKB1 IL1B CASP3
4 protein phosphorylation GO:0006468 10.16 PAK1 MET EGFR CHUK CCL5 ADAM10
5 negative regulation of apoptotic process GO:0043066 10.13 NFKBIA NFKB1 IL10 EGFR CASP3 ADAM10
6 intracellular signal transduction GO:0035556 10.11 NOD1 EGFR CXCL8 CXCL1 CASP3
7 positive regulation of transcription, DNA-templated GO:0045893 10.08 TNF NFKBIA NFKB1 JUN IL1B IL10
8 positive regulation of cell migration GO:0030335 10.03 PAK1 IL1B EGFR CCL5 ADAM10
9 positive regulation of protein phosphorylation GO:0001934 10.01 TNF PAK1 IL1B EGFR
10 positive regulation of ERK1 and ERK2 cascade GO:0070374 10.01 TNF PTPN11 NOD1 EGFR CCL5
11 positive regulation of protein kinase B signaling GO:0051897 10 TNF PTPN11 MET EGFR
12 Fc-epsilon receptor signaling pathway GO:0038095 9.99 PAK1 NFKB1 JUN CHUK
13 defense response GO:0006952 9.99 TNF NOD1 CXCL8 CXCL1
14 MAPK cascade GO:0000165 9.97 TNF PAK1 MET IL1B EGFR CCL5
15 activation of MAPK activity GO:0000187 9.95 TNF PTPN11 NOD1 IL1B
16 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.95 TNF NOD1 NFKB1 IL1B CHUK
17 response to virus GO:0009615 9.94 TNF IFNGR1 CHUK CCL5
18 positive regulation of inflammatory response GO:0050729 9.92 TNF NFKBIA IL1B EGFR
19 positive regulation of interleukin-6 production GO:0032755 9.92 TNF PTPN11 NOD1 IL1B
20 immune response GO:0006955 9.92 TNF IL1RN IL1B IL10 CXCL8 CXCL1
21 cellular response to tumor necrosis factor GO:0071356 9.91 NFKBIA NFKB1 CXCL8 CHUK CCL5
22 neutrophil chemotaxis GO:0030593 9.9 CXCL8 CXCL1 CCL5
23 regulation of insulin secretion GO:0050796 9.9 TNF IL1B CCL5
24 chemokine-mediated signaling pathway GO:0070098 9.9 CXCL8 CXCL1 CCL5
25 cellular response to mechanical stimulus GO:0071260 9.9 PTPN11 NFKB1 IL1B EGFR
26 I-kappaB kinase/NF-kappaB signaling GO:0007249 9.89 TNF NFKBIA CHUK
27 positive regulation of interleukin-8 production GO:0032757 9.88 TNF NOD1 IL1B
28 cellular response to organic cyclic compound GO:0071407 9.88 TNF IL1B CCL5 CASP3
29 response to lipopolysaccharide GO:0032496 9.88 NFKBIA JUN IL1B IL10 CHUK CASP3
30 positive regulation of neuron apoptotic process GO:0043525 9.87 TNF JUN CASP3
31 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.87 TNF NOD1 IL1B EGFR
32 response to glucocorticoid GO:0051384 9.86 TNF IL1RN IL10 CASP3
33 positive regulation of pri-miRNA transcription by RNA polymerase II GO:1902895 9.85 TNF JUN IL10
34 protein kinase B signaling GO:0043491 9.85 TNF IL1B CCL5
35 cellular response to reactive oxygen species GO:0034614 9.85 JUN EGFR CHUK
36 cellular response to lipopolysaccharide GO:0071222 9.85 TNF NFKB1 IL1B IL10 CXCL8 CXCL1
37 cellular response to cadmium ion GO:0071276 9.84 JUN EGFR CHUK
38 negative regulation of mitotic cell cycle GO:0045930 9.84 TNF IL10 EGFR
39 positive regulation of smooth muscle cell proliferation GO:0048661 9.84 TNF JUN EGFR CCL5
40 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.83 TNF PAK1 JUN IL10
41 positive regulation of JAK-STAT cascade GO:0046427 9.82 TNF IL10 CCL5
42 positive regulation of amyloid-beta formation GO:1902004 9.78 TNF IFNGR1 CASP3
43 astrocyte activation GO:0048143 9.77 TNF IFNGR1 EGFR
44 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.76 TNF IL1B IL10
45 lipopolysaccharide-mediated signaling pathway GO:0031663 9.76 TNF NFKBIA IL1B CCL5
46 regulation of establishment of endothelial barrier GO:1903140 9.73 TNF IL1B
47 interleukin-1-mediated signaling pathway GO:0070498 9.73 NOD1 NFKBIA NFKB1 IL1RN IL1B CHUK
48 cellular response to nicotine GO:0071316 9.72 TNF NFKB1
49 negative regulation of lipid storage GO:0010888 9.72 TNF NFKBIA
50 endothelial cell apoptotic process GO:0072577 9.71 TNF IL10

Molecular functions related to Helicobacter Pylori Infection according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein-containing complex binding GO:0044877 9.65 NOD1 JUN EGFR CHUK CASP3
2 identical protein binding GO:0042802 9.61 TNF PAK1 NOD1 NFKBIA NFKB1 MET
3 chemokine activity GO:0008009 9.33 CXCL8 CXCL1 CCL5
4 cytokine activity GO:0005125 9.17 TNF IL1RN IL1B IL10 CXCL8 CXCL1

Sources for Helicobacter Pylori Infection

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....